502 related articles for article (PubMed ID: 18177922)
61. Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments for the motion.
Hunt RH
Can J Gastroenterol; 2003 May; 17(5):339-41. PubMed ID: 12772010
[TBL] [Abstract][Full Text] [Related]
62. [Coxiber and risk of myocardial infarction--the apprehension might have been exaggerated].
Oliw E; Aly A
Lakartidningen; 2002 Dec; 99(50):5082-4, 5087. PubMed ID: 12572300
[TBL] [Abstract][Full Text] [Related]
63. Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease.
Johnson J; Weinryb J
J Natl Med Assoc; 2006 Jul; 98(7):1126-35. PubMed ID: 16895283
[TBL] [Abstract][Full Text] [Related]
64. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Hawkey CJ; Gitton X; Hoexter G; Richard D; Weinstein WM
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):57-66. PubMed ID: 16431306
[TBL] [Abstract][Full Text] [Related]
65. The causes and effects of socio-demographic exclusions from clinical trials.
Bartlett C; Doyal L; Ebrahim S; Davey P; Bachmann M; Egger M; Dieppe P
Health Technol Assess; 2005 Oct; 9(38):iii-iv, ix-x, 1-152. PubMed ID: 16181564
[TBL] [Abstract][Full Text] [Related]
66. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?
Nielsen OH; Ainsworth M; Csillag C; Rask-Madsen J
Aliment Pharmacol Ther; 2006 Jan; 23(1):27-33. PubMed ID: 16393277
[TBL] [Abstract][Full Text] [Related]
67. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.
Weberschock TB; Müller SM; Boehncke S; Boehncke WH
Arch Dermatol Res; 2007 Jul; 299(4):169-75. PubMed ID: 17492455
[TBL] [Abstract][Full Text] [Related]
68. Pharmacological therapy of osteoarthritis.
Hochberg MC; Dougados M
Best Pract Res Clin Rheumatol; 2001 Oct; 15(4):583-93. PubMed ID: 11567541
[TBL] [Abstract][Full Text] [Related]
69. Cardiovascular risk, hypertension, and NSAIDs.
White WB
Curr Rheumatol Rep; 2007 Apr; 9(1):36-43. PubMed ID: 17437665
[TBL] [Abstract][Full Text] [Related]
70. [Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions].
Bannwarth B
Presse Med; 2002 Sep; 31(31):1469-75. PubMed ID: 12395741
[TBL] [Abstract][Full Text] [Related]
71. Rofecoxib: clinical pharmacology and clinical experience.
Weaver AL
Clin Ther; 2001 Sep; 23(9):1323-38. PubMed ID: 11589252
[TBL] [Abstract][Full Text] [Related]
72. Current status of nonsteroidal anti-inflammatory drugs in physiatry: balancing risks and benefits in pain management.
Kaplan RJ
Am J Phys Med Rehabil; 2005 Nov; 84(11):885-94. PubMed ID: 16244527
[TBL] [Abstract][Full Text] [Related]
73. Treatment of osteoarthritis with acetaminophen: efficacy, safety, and comparison with nonsteroidal anti-inflammatory drugs.
Shamoon M; Hochberg MC
Curr Rheumatol Rep; 2000 Dec; 2(6):454-8. PubMed ID: 11123097
[TBL] [Abstract][Full Text] [Related]
74. Pathophysiology and first-line treatment of osteoarthritis.
Hogue JH; Mersfelder TL
Ann Pharmacother; 2002 Apr; 36(4):679-86. PubMed ID: 11918520
[TBL] [Abstract][Full Text] [Related]
75. Update of ACR guidelines for osteoarthritis: role of the coxibs.
Schnitzer TJ;
J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S24-30; discussion S31-4. PubMed ID: 11992747
[TBL] [Abstract][Full Text] [Related]
76. Cyclooxygenase-2 inhibitors: a painful lesson.
Sanghi S; MacLaughlin EJ; Jewell CW; Chaffer S; Naus PJ; Watson LE; Dostal DE
Cardiovasc Hematol Disord Drug Targets; 2006 Jun; 6(2):85-100. PubMed ID: 16787194
[TBL] [Abstract][Full Text] [Related]
77. [Selective COX-2 inhibitors: do they retain any gastroduodenal toxicity].
Bannwarth B
Gastroenterol Clin Biol; 2004 Apr; 28 Spec No 3():C90-5. PubMed ID: 15366680
[TBL] [Abstract][Full Text] [Related]
78. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review.
Rostom A; Muir K; Dubé C; Jolicoeur E; Boucher M; Joyce J; Tugwell P; Wells GW
Clin Gastroenterol Hepatol; 2007 Jul; 5(7):818-28, 828.e1-5; quiz 768. PubMed ID: 17556027
[TBL] [Abstract][Full Text] [Related]
79. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.
Zeng C; Wei J; Persson MSM; Sarmanova A; Doherty M; Xie D; Wang Y; Li X; Li J; Long H; Lei G; Zhang W
Br J Sports Med; 2018 May; 52(10):642-650. PubMed ID: 29436380
[TBL] [Abstract][Full Text] [Related]
80. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.
Sciulli MG; Capone ML; Tacconelli S; Patrignani P
Pharmacol Rep; 2005; 57 Suppl():66-85. PubMed ID: 16415488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
